

Current role

Medical oncologist specializing in thoracic malignancies, with institutional leadership roles as program director for immunotherapy, leader of the molecular tumor board, and academic lead for thoracic medical oncology.

Education and training

Fellowship July 2019-June 2021	Hematology & Oncology Washington University St. Louis, MO
July 2018-June 2019	Hematology & Oncology Loma Linda University Loma Linda, CA
Graduate October 2016-May 2018	Master of Business Administration Washington University St. Louis, MO
Residency July 2008-June 2011	Internal Medicine University of New Mexico Albuquerque, NM
Doctorate August 2000-May 2006	Bachelor of Medicine and Bachelor of Surgery Smt. NHL Municipal Medical College Ahmedabad, India

Employment history

- Northshore Department of Medicine, Assistant Professor, University Of Chicago, IL- Medical Oncologist July 2025-
- St. Luke's Hospital, Assistant Professor, University of Missouri, Kansas City, MO- Medical Oncologist 2021-2025
- Barnes Jewish Hospital, Saint Louis, MO- Hospitalist 2014-2018
- St. Anthony Health Center, Alton, IL- Primary Care Physician, Hospitalist 2011-2014

Peer-Reviewed Publications

- Successful rechallenge of BRAF/MEK Inhibitor with Ruxolitinib in BRAF/MEK Inhibitor-Induced Hemophagocytic Lymphohistiocytosis Like Hyperinflammatory Syndrome in BRAF V600E-Mutated Lung Adenocarcinoma: A Case Report. *Frontiers in Oncology*. May 2026
Chandra S, Hansraj S, Adhikari A, Ponvilawan B, Tolentino A, **Bansal D**
- Immunotherapy Response and Survival Outcome by Immunophenotypic Signature in Non-Small Cell Lung Cancer. *JCP Precision Oncology*. May 2026
Bansal D, Ponvilawan V, Grachev D, Kushnarev V, Tarasov A, Valiev I, Danilov K, Butusova A, Turova P, Bagaev A, Kotlov N, Al-Obaidi A, Ward C, Subramanian J
- Tumor Metrics Imaging Core Labs: Primer for Radiologists. *Abdominal Radiology*. February 2026
Gurudu R, **Bansal D**, Chauhan A, Tirumani S
- Immune Checkpoint Inhibitor-Induced Hemophagocytic Lymphohistiocytosis: A Case Series. *Exploration of Targeted Anti-tumor Therapy*. November 2025.
Khan AW, Chandra S, Mahadevia H, Subramanian J, Ponvilawan B, **Bansal D**
- Long-term Survival Outcomes by Number of ICI in PD-L1 Negative Metastatic NSCLC: A Meta-analysis. *JAMA Network Open*. February 2025
Ponvilawan B, **Bansal D**, Nagla A, Ramakrishna R, Subramanian J
- The Number of Chemoimmunotherapy Cycles and Clinical Outcomes in Resectable NSCLC. *Journal of Thoracic Oncology*. August 2024.
Ponvilawan B, Subramanian J, **Bansal D**

- Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma. *The oncologist*. July 2024
Botta G, Abdelrahim M, Drengler R, Aushev V, Esmail A, Laliotis G, Brewer C, George G, Abbate S, Chandana S, Tejani M, Malla M, **Bansal D**, Rivero-Hinojosa S, Spickard E, McCormick N, Cecchini M, Lacy J, Fei N, Kasi, Anup Kasi P, Dayyani F, Hanna D, Sharma S, Malhotra M, Aleshin A, C Liu M, Jurdi A
- A Novel EGFR Germline Mutation in Lung Adenocarcinoma: Case Report and Literature Review. *Clinical Lung Cancer*. April 2024
Sharma P, Mahadevia H, Donepudi S, Kujtan L, Gustafson B, Ponvilawan B, Al-obaidi A, Subramanian J, **Bansal D**
- Exceptional synergistic response of PARP inhibitor and immune checkpoint inhibitor in esophageal adenocarcinoma with a germline BRCA2 mutation: a case report. *Therapeutic Advances in Medical Oncology*. March 2024
Mahadevia H, Ponvilawan B, Al-Obaidi A, Buckley J, Subramanian J, **Bansal D**
- Non-Invasive Predictive Biomarkers for Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors. *Cancers*. March 2024.
Ponvilawan B, Khan A, Subramanian J, **Bansal D**
- Evaluating the Impact of Perioperative Immune Checkpoint Inhibitor in the Treatment of Patients with Resectable Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. *Clinical Lung Cancer*. February 2024
Ponvilawan B, Mahadevia H, Qasim H, Sharma P, **Bansal D**, Subramanian J
- Response to osimertinib in a colorectal cancer patient with an EGFR T790M mutation: A case report. *World Journal of Gastrointestinal Oncology*. October 2023.
Buzard B, Douglass L, Gustafson B, Buckley J, Roth M, Kujtan L, **Bansal D**
- Utility of RNA Expression to Determine the Tissue of Origin of Malignancies with an Inconclusive Histopathology. *Case Reports in Oncology*. September 2023.
Mahadevia H, Kujtan L, Roth M, Sharma P, Buckley J, Ewing E, **Bansal D**
- Outcomes of Immunotherapy Versus Chemotherapy as First-Line Treatment in Advanced NSCLC: A Meta-Analysis of Randomized Clinical Trials. *Journal of Thoracic Oncology*. August 2023.
Ponvilawan B, Sharma P, Mahadevia H, Subramanian J, **Bansal D**
- Transmission of Lung Adenocarcinoma From a Single Donor in 2 Transplant Recipients: A Case Report with Literature Review. *Transplant Proceedings*. August 2023.
Arsenault A, Sharma P, Buckley J, Braun A, Ewing E, Rakhra S, Cummings L, **Bansal D**
- Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer. *Cancers*. January 2021.
Bansal D, Reimers MA, Knoche EM, Pachynski RK
- Lenalidomide results in a durable complete remission in acute myeloid leukemia accompanied by persistence of somatic mutations and a T cell infiltrate in the bone marrow. *Haematologica*. March 2018.
Bansal D, Vij K, Chang GS, Miller CA, DiPersio JF, Vij R, Heath S, Westervelt P, Welch JS, Fehniger TA
- Proteasome Inhibitor Associated Thrombotic Microangiopathy. *American Journal of Hematology*. September 2016.
Yui JC, Van Keer J, Weiss BM, Waxman AJ, Palmer MB, D'Agati VD, Kastritis E, Dimopoulos MA, Vij R, **Bansal D**, Dingli D, Nasr SH, Leung N

Clinical trial design

- Designed the phase 1 CABIOS trial- Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (NCT04477512), which has finished accrual at Washington University

Principal Investigator- Saint Luke's Cancer Institute, Kansas City

- A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (October 2024- February 2025)
- Palbociclib and Cetuximab versus Cetuximab Monotherapy for Patients with CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma who Experienced Disease Progression on a PD-1/L1 Inhibitor: A Multicenter, Open-Label, Randomized Phase 3 Trial (October 2024- February 2025)

- A randomized, phase 3, open-label study to evaluate SGN-B6A compared with docetaxel in adult subjects with previously treated non-small cell lung cancer (July 2024-November 2025)
- Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (5/2024-February 2025)
- A Phase I study of ABBV-706 monotherapy and in combination with budigalimab (ABBV-181), carboplatin, or cisplatin in adult subjects with advanced solid tumors (4/2024-February 2025)
- A Randomized Phase II Study of Tepotinib with or Without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (A Lung-MAP Treatment Trial) (1/2024-February 2025)
- Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC (An Alchemist Treatment Trial) (7/2023-February 2025)
- Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study (March 2023-February 2025)
- Bespoke study of ctDNA Guided Therapy in Colorectal Cancer (7/2022-3/2023)
- Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study (7/2022-8/2023)
- A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT) (7/2022-8/2023)
- Crizotinib in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An Alchemist Treatment Trial) ((7/2022-February 2025)
- Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-Squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) (7/2022-February 2025)
- A Phase II Study of Selpercatinib in Patients with RET fusion-positive Stage IV or Recurrent Non-Small Cell Lung Cancer (A Lung-MAP Treatment Trial) (7/2022-12/2023)
- Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer (7/2022-12/2023)
- Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First-Line Treatment and Maintenance in Non-small Cell Lung Cancer, the Insignia clinical trial (7/2022-3/2024)
- Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) (12/2022-February 2025)

Published Abstracts

- Machine-learning tool Helenus enhances gene expression profiling to improve biomarker discovery in lung adenocarcinoma cohorts and advance the precision of immunotherapy. *Journal for Immunotherapy of Cancer*. November 2025. N. Khotkina, D. Bansal, A.Bagaev et al
- Clonal hematopoiesis and its association with lung cancer incidence and immunotherapy response: a meta-analysis. *Journal of Thoracic Oncology*. December 2025. B Ponvilawan, S Subramanian, D Bansal et al.
- High tertiary lymphoid structure predicts immune checkpoint inhibitor response and survival outcomes in patients with non-small cell lung cancer. *Journal of Clinical Oncology*. June 2025. Danilov K, Bansal D, Fowler N, et al.
- A Phase 1b study of cabozantinib, nivolumab, with abiraterone (CABIOS) in metastatic castration-sensitive prostate cancer (mCSPC): updated safety, efficacy, and immunologic findings. *Journal of Clinical Oncology*. February 2025. P Matthews, D Bansal, R Pachynski
- Survival outcomes in single versus double immune checkpoint inhibitor in advanced non-small cell lung cancer: a meta-analysis. *Journal of Thoracic Oncology*. September 2024. B. Ponvilawan, Mahadevia H, Khan A, J. Subramanian, D. Bansal
- Downregulation of Immune-Mediated Pathways in Lung Adenocarcinoma with *KEAP1* or *STK11* Mutation. *Journal of Thoracic Oncology*. December 2023. B. Ponvilawan, D. Bansal, J. Subramanian.
- A Cross-Cohort Examination of Factors Impacting Immunotherapy Survival in Non-Small Cell Lung Cancer. *Journal for Immunotherapy of Cancer*. November 2023. K. Danilov, D. Bansal, A.Bagaev et al
- Molecular Tumor Board Directed Treatment for Patients with Advanced Stage Solid Tumors: A Case-Control Study. *ESMO congress*. October 2023. Dhruv Bansal, Janakiraman Subramanian et al
- Outcomes of Immunotherapy vs Chemotherapy as First-Line Treatment in Advanced NSCLC: A Meta-analysis of Randomized Clinical Trials. *World Conference on Lung Cancer*. September 2023. B. Ponvilawan, D. Bansal et al

- NSCLC Microenvironment Subtypes Correlate with Response and Survival to Immune Checkpoint Inhibitor Therapy. *World Conference on Lung Cancer*. September 2023. K. Danilov, D. Bansal, N. Fowler, et al.
- Immunotherapy versus Chemotherapy in the Management of Resectable Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Clinical Trials. *World Conference on Lung Cancer*. September 2023. Ben Ponvilawan, D. Bansal et al
- A Pilot Trial of Neoantigen DNA Vaccine in Combination with Nivolumab/Ipilimumab and Prostavac in Metastatic Hormone-Sensitive Prostate Cancer. *Journal of Clinical Oncology*. February 2021. D Bansal, R Pachynski
- Prostate cancer cost-of-care and evaluation of traditional cost control measures. *Journal of Clinical Oncology*. February 2019. D Bansal, J Wong
- Pancreatic Cancer- Cost of Care in Inpatient Setting. *Journal of Clinical Oncology*. March 2017. D Bansal, V Kapoor, et al
- Cost of Colon Cancer Care: Results of Nationwide Inpatient Sample (NIS) Data. *Journal of Clinical Oncology*. February 2017. P Bansal, D Bansal et al
- Post-Transplant in AML Patients 60 Years of Age Beyond CR1. *Blood*. December 2016. Dhruv Bansal, Rizwan Romee, et al.
- Comparable Survival with HLA Haploidentical and Mismatched Unrelated Donor Transplant in Patients with AML and MDS. *Biology of Blood and Marrow Transplantation*. September 2016. Dhruv Bansal, Rizwan Romee, et al.

Select Oral Presentations

- Antibiotics and Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Vumedi. April 1, 2026
- Impact of Timing on Immunotherapy Outcomes in Non-Small Cell Lung Cancer. Vumedi. February 6, 2026
- Bispecific T-Cell Engager Therapies Currently Approved for Solid Tumors. Vumedi. January 22, 2026
- Bispecific T-Cell Engager Therapies for Non-Heme Malignancies. Endeavor Health Oncology Grand Rounds. January 8, 2026
- Immunotherapy: The Good, the Bad, and the Itchy. Endeavor Health Medicine Grand Rounds. October 17, 2025
- Immunotherapy: Side Effects and Management. Vumedi. October 16, 2025
- Treating Unresectable Stage III NSCLC. Updates in Thoracic Oncology from the Masters. September 27, 2025
- Immunotherapy Response and Survival Outcome by Immunophenotypic Signature in Non-Small Cell Lung Cancer. Hawaii Lung Global Summit. June 26, 2025
- Neoadjuvant and Perioperative Chemoimmunotherapy in Resectable Non-Small Cell Lung Cancer. Hawaii Lung Global Summit. June 25, 2025
- NSCLC Microenvironment Subtypes Correlate with Response and Survival to Immune Checkpoint Inhibitor Therapy. Northshore Hospital oncology grand rounds. October 18, 2024
- WCLC 2023 Insights: "NSCLC Microenvironment Subtypes Correlate with Response and Survival to Immune Checkpoint Inhibitor Therapy. VuMedi. October 22, 2023
- Combination therapies for metastatic hormone-sensitive prostate cancer. GU lecture series. University of Missouri-Kansas City, March 16, 2022
- Discovering an immunologic beachhead in the prostate tumor microenvironment. Oncology grand rounds, Washington University, March 12, 2021
- Choosing the best anticoagulant for my patient. Hematology grand rounds, Washington University, March 6, 2020

Media Interviews, newsletters & Podcasts

- *Current Innovations in Precision Medicine in Cancer Treatment*. **Becker's Healthcare Podcast**. Invited expert interview. 2025.
- *Why Cancer Survivorship Care Needs a Redesign, per 10 Leaders*. **Becker's Oncology**. Expert commentary featured in national oncology industry newsletter highlighting the need for longitudinal, integrated survivorship care models. 2026.
- **YouTube Channel (Educational Oncology Media)**. Creator of an educational oncology channel covering thoracic oncology, melanoma, and immunotherapy, featuring evidence-based commentary on emerging data, clinical trials, and real-world treatment decision-making for physicians and trainees. February 2026.
- Speaker, *Oncology 2030: The Future of Treatments, Workforce, and Beyond* — **Becker's Oncology Virtual Event**, March 2026

Poster Presentations

- Khotkina N, Bansal D, Bagaev A et al. Machine-learning tool Helenus enhances gene expression profiling to improve biomarker discovery in lung adenocarcinoma cohorts and advance the precision of immunotherapy. SITC annual meeting. November 2025.
- Ponvilawan B, Subramanian S, Bansal D et al. Clonal hematopoiesis and its association with lung cancer incidence and immunotherapy response: a meta-analysis. IASLC annual meeting. September 2025.
- Danilov K, Bansal D, Fowler N, et al. High tertiary lymphoid structure predicts immune checkpoint inhibitor response and survival outcomes in patients with non-small cell lung cancer. *Journal of Clinical Oncology*. ASCO Annual Meeting. June 2025
- P Matthews, D Bansal, R Pachynski. A Phase 1b study of cabozantinib, nivolumab, with abiraterone (CABIOS) in metastatic castration-sensitive prostate cancer (mCSPC): updated safety, efficacy, and immunologic findings. ASCO Genitourinary Cancer Symposium. February 2025
- B. Ponvilawan, D. Bansal, J. Subramanian. Downregulation of Immune-Mediated Pathways in Lung Adenocarcinoma with *KEAP1* or *STK11* Mutation. NACLC Annual Meeting. December 2023
- Konstantin Danilov, Dhruv Bansal, Alexander Bagaev, et al. A Cross-Cohort Examination of Factors Impacting Immunotherapy Survival in Non-Small Cell Lung Cancer. SITC annual meeting. November 2023.
- D. Bansal, J. Subramanian et al. Molecular Tumor Board Directed Treatment for Patients with Advanced Stage Solid Tumors: A Case-Control Study. ESMO annual congress. October 2023.
- B. Ponvilawan, D. Bansal et al. Outcomes of Immunotherapy vs Chemotherapy as First-Line Treatment in Advanced NSCLC: A Meta-analysis of Randomized Clinical Trials. IASLC annual meeting. September 2023.
- K. Danilov, D. Bansal, N. Fowler et al. NSCLC Microenvironment Subtypes Correlate with Response and Survival to Immune Checkpoint Inhibitor Therapy. IASLC annual meeting. September 2023.
- Ben Ponvilawan, D. Bansal et al. Immunotherapy versus Chemotherapy in the Management of Resectable Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Clinical Trials. IASLC annual meeting. September 2023.
- J Zaretsky, D Bansal, R Pachynski. CABIOS Trial: A phase 1b study of cabozantinib and nivolumab in combination with abiraterone in patients with metastatic hormone-sensitive prostate cancer (mHSPC). ASCO Annual Conference. June 2023
- K Shah, D Bansal, R Pachynski. A Pilot Trial of Neoantigen DNA Vaccine in Combination with Nivolumab/ipilimumab and Prostavac in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC). ASCO Annual Conference. June 2022
- D Bansal, R Pachynski. A Pilot Trial of Neoantigen DNA Vaccine in Combination with Nivolumab/ipilimumab and Prostavac in Metastatic Hormone-Sensitive Prostate Cancer. ASCO Genitourinary Cancer Symposium. February 2021
- D Bansal, J Wong. Prostate cancer cost-of-care and evaluation of traditional cost control measures. ASCO Genitourinary Cancer Symposium. February 2019
- D Bansal, P Bansal, V Kapoor. Pancreatic cancer- cost of care in inpatient setting. ASCO Quality Care Symposium. March 2017
- P Bansal, D Bansal et al. Cost of Colon Cancer Care: Results of Nationwide Inpatient Sample (NIS) Data. ASCO Gastrointestinal Cancer Symposium January 2017
- Dhruv Bansal, Rizwan Romee, et al. Post-Transplant in AML Patients 60 Years of Age Beyond CR1. American Society of Hematology Annual Meeting. December 2016
- Dhruv Bansal, Rizwan Romee, et al. Comparable Survival with HLA Haploidentical and Mismatched Unrelated Donor Transplant in Patients with AML and MDS. America Society for Blood and Marrow Transplantation Annual Tandem Meeting. February 2016

Bench Research

- Deretic Lab, Crohn's disease and gene modulation 2010
University of New Mexico, Albuquerque, NM

Grants

- Received grant from Boston Gene to conduct biomarker discovery on NSCLC samples 2024

- Auxiliary Research Scholar Award 2026–2028
NorthShore Hospitals Foundation of Endeavor Health
Principal Investigator
\$150,000 total (\$50,000/year × 3 years)
Project: *Circulating tumor DNA–guided clinical trial in small cell lung cancer*

Book Chapters

- Acute leukemias chapter for The Washington Manual of Oncology: 4th edition. 2021
- Myelodysplastic syndromes chapter for The Washington Manual of Oncology: 4th edition. 2021
- Acute leukemias chapter for DeVita Principles and Practice of Oncology Review: 5th edition. 2021
- Myelodysplastic syndromes chapter for DeVita Principles and Practice of Oncology Review: 5th edition. 2021
- Myelodysplastic Syndrome chapter for Decision Support in Medicine: Hospital Medicine: 2nd edition. 2016
- Chronic Myelogenous Leukemia chapter for Decision Support in Medicine: Hospital Medicine: 2nd edition. 2016

Leadership experience

- Emerging Leader Program, Endeavor Health — Selected Participant July 2026–December 2026
- West Community Lung Cancer Steering Committee, Johnson and Johnson 2026
- Program Director for Immunotherapy, Kellogg Cancer Center, IL June 2025- present
- Lead, Molecular Tumor Board, Kellogg Cancer Center, IL June 2025- present
- Academic Lead for Thoracic Medical Oncology, Kellogg Cancer Center, IL June 2025- present
- Site lead, Thoracic Oncology, Hoosier Cancer Research Network 2024-2025
- Alliance Respiratory Committee 2023-present
- Saint Luke's Credentialing Committee 2022-present
- Director, Precision and Thoracic Oncology, St. Luke's Hospital, Kansas City 2022- present
- ASCO CancerLinQ Physician Advisory Committee 2021-2023
- St. Louis Society of Hospital Medicine, Secretary 2013-2017
- Hospice Director, St. Anthony's Health Center, Alton, IL 2011-2014
- Pharmacy Director, St. Anthony's Health Center, Alton, IL 2011-2012

Volunteer Work

- Volunteer Auditor, Alliance for Clinical Trials in Oncology 2025-present
- Prayas-Indian NGO, Medical Services Volunteer 2005-2006
- Indian Red Cross, Medical Services Volunteer 2001-2006

Honors and Awards

- Panelist, ACCC Precision Medicine Summit 2025
- Novel Precision Medicine Workflow-Association of Cancer Care Centers 2024
- Excellence in Teaching at the University of Missouri in Kansas City 2024
- Accelerating Anticancer Agent Development and Validation Workshop 2021
- Cancer Genomics and Outcomes Research R25 STRENGTH (Short-Term Research Education and Growth Through Hands-On Experiences) Program Scholar 2019
- Distinguished Faculty Award, Washington University School of Medicine 2017
- Platinum Chapter Award, Society of Hospital Medicine 2016

Institutional service

- Institutional Review Board (IRB) — Member, Endeavor Health 2026-
- Project ORBIT: Led system-wide integration of oncology clinical trials across the newly unified Endeavor Health network, streamlining activation processes, enhancing data governance, and expanding trial access across all sites 2025-2026
- Introduced bite therapies, Saint Luke's Cancer Institute 2024

- Moderator, Precision Oncology Tumor Board, Saint Luke's Cancer Institute 2021-2025
- Moderator, Midwest Precision Oncology Conference, Saint Luke's Cancer Institute 2021-2025
- Member, Medical Informatics Council. Saint Luke's Hospital 2022-2025
- Moderator, Epic Genomics Integration Committee 2022-2025
- Moderator, Thoracic Oncology Tumor Board, Saint Luke's Cancer Institute 2021-2025

Peer-Review Activities

- **The Oncologist.** Completed peer review of manuscript titled “Immune-related adverse events, survival outcomes, and next steps in stage III melanoma: Real-world experience at an NCI comprehensive cancer center.” October 2025
- **Translational Lung Cancer Research** — Invited Reviewer, 2026–present

Not yet retained